Scientific Programme

Sunday | Monday | Tuesday | Wednesday  

ECIO 2017 Preliminary Programme (PDF download 570 KB)

 

Sunday, April 23

   
  08:30-10:00, Main Auditorium (Sala A1)
  Clinical Focus Session
CF 101 Colorectal cancer patients – the challenge
   
  Moderators: A. Cervantes (Valencia/ES), A. Gangi (Strasbourg/FR)
   
101.1
 
101.2
 
101.3
 
101.4
101.5
 
101.6
 
Demographics and need for treatment
A. Cervantes (Valencia/ES)
Treatment strategies according to the new ESMO guidelines
D. Arnold (Lisbon/PT)
Who is the ideal candidate for liver surgery?
P. Bachellier (Strasbourg/FR)
Invited scientific paper
Local ablation in oligometastatic disease
A. Gillams (London/UK)
Intra-arterial therapies in advanced metastases
P.L. Pereira (Heilbronn/DE)
   
   
  10:30-12:00, Auditorium 2 (Barria Room 1)
  Clinical Focus Session
CF 201 Immunotherapy for cancer
   
  Moderators: J.-F.H. Geschwind (New Haven, CT/US), P. Sarobe (Pamplona/ES)
   
201.1
 
201.2
 
201.3
 
201.4
 
201.5
 
Cancer and immune reaction
J.J. Lasarte (Pamplona/ES)
Immunoscore: is it more relevant than TNM?
J. Rodríguez (Pamplona/ES)
Checkpoint inhibitors
M. Fuchs (Munich/DE)
Tumour exosomes – determination of organotropic metastases
B. Costa-Silva (Lisbon/PT)
IO and immunotherapy in cancer
J.P. Erinjeri (New York, NY/US)
   
   
  10:30-12:00, Main Auditorium (Sala A1)
  Clinical Focus Session
CF 202 Colorectal cancer and IO: where is the evidence?
   
  Moderator: P. Gibbs (Melbourne, VIC/AU)
   
202.1
 
202.2
 
202.3
 
202.4
 
202.5
 
CLOCC trial in detail
O.M. van Delden (Amsterdam/NL)
Evidence for surgery as a curative treatment
A. Denys (Lausanne/CH)
SIRFLOX trial in detail
P. Gibbs (Melbourne, VIC/AU)
Does progression-free survival translate into overall survival?
R. Sharma (London/UK)
Evidence in endpoints for IO in CRC mets
T.K. Helmberger (Munich/DE)
   
   
  10:30-12:00, HDT Room (Sala A3)
  Hands-on Device Training
TA-HDT 1 Tumour ablation – Radiofrequency
   
  Please click here for further details.
   
   
  13:00-14:30
  Satellite Symposia
   
   
  15:00-16:30, Main Auditorium (Sala A1)
  Multidisciplinary Tumour Board
MTB 401 CRC metastases – beyond the guidelines
   
  Coordinator: T.K. Helmberger (Munich/DE)
   
  Panellists: D.J. Breen (Southampton/UK), A. Cervantes (Valencia/ES),
T. de Baère (Villejuif/FR), C.R. Ferrone (Boston, MA/US)
   
   
  15:00-16:30, Auditorium 2 (Barria Room 1)
  Technical Focus Session
TF 402 Cutting-edge developments
   
  Moderators: K. Malagari (Athens/GR), J. Ricke (Magdeburg/DE)
   
402.1
 
402.2
 
402.3
 
402.4
 
 
 
 
 
 
402.5
 
402.6
 
Drug-eluting particles
R. Duran (Lausanne/CH)
Thermal ablation
L. Crocetti (Pisa/IT)
Radioembolisation
M. van den Bosch (Utrecht/NL)
Invited scientific paper: Antitumour magnetic hyperthermia induced by RGD functionalized Fe3O4 nanoparticles, in an experimental model of colorectal liver metastases
O.K. Arriortua1, E. Garaio1, B. Herrero de la Parte1, M. Insausti1,2, L. Lezama1,2, F. Plazaola1, J. Angel García1,2, J.M. Aizpurua3, M. Sagartzazu3, M. Irazola1,
N. Etxebarria1, I. García-Alonso1, A. Saiz-López4, J.J. Echevarria-Uraga4; 1Bilbao/ES, 2Derio/ES, 3Donostia/ES, 4Galdakao/ES

Intratumoural immunotherapy and viral therapy
L. Tselikas (Villejuif/FR)
Immunotherapy plus ablation or DEB-TACE
B.J. Wood (Bethesda, MD/US)
   
   
  15:00-16:30, HDT Room (Sala A3)
  Hands-on Device Training
TA-HDT 2 Tumour ablation – Radiofrequency
   
  Please click here for further details.
   
   
  17:00-18:30, Main Auditorium (Sala A1)
  Clinical Focus Session
CF 501 Follow the colorectal cancer patients: quality and efficacy
   
  Moderators: A. Adam (London/UK), B. Gebauer (Berlin/DE)
   
501.1
 
501.2
 
501.3
 
501.4
 
501.5
 
What are the guidelines?
R. Vera (Pamplona/ES)
Does expensive and short-term imaging follow-up affect the outcome?
R.G.H. Beets-Tan (Amsterdam/NL)
PET-CT: a critical review
N. Schäfer (Lausanne/CH)
PRO, PCO and PREM – what do they tell us?
P. Reimer (Karlsruhe/DE)
Changing healthcare systems: what are convincing outcome measures?
I. Durand-Zaleski (Paris/FR)
   
   
  17:00-18:30, Auditorium 2 (Barria Room 1)
  Clinical Focus Session
CF 502 Getting IO into practice
   
  Moderators: J. Lammer (Vienna/AT), R.A. Morgan (London/UK)
   
502.1
 
502.2
 
502.3
 
502.4
 
502.5
 
Curriculum in IO
P.P. Rao (Dombivli/IN)
How to increase patient referral
T.F. Jakobs (Munich/DE)
Patient pathway in IO
J. Ricke (Magdeburg/DE)
Interaction with other disciplines
J.I. Bilbao (Pamplona/ES)
How do I promote IO services to my administration?
R.-T. Hoffmann (Dresden/DE)
   
   
  18:30-19:15
  Satellite Symposium
   

 

TOP
 

Monday, April 24

   
  07:45-08:15
  Satellite Symposium
   
   
  08:30-10:00, Main Auditorium (Sala A1)
  Clinical Focus Session
CF 801 Lung metastases
   
  Moderators: A. Gillams (London/UK), U. Martens (Heilbronn/DE)
   
801.1
 
801.2
 
801.3
 
 
 
 
 
 
 
 
801.4
 
801.5
 
801.6
Rationale for local treatment – does it help patients?
I. Gil-Bazo (Pamplona/ES)
Resection – current status and evidence
T. Treasure (London/UK)
Invited scientific paper: Multi-center study of metastatic lung tumors targeted by interventional cryoablation evaluation (SOLSTICE): preliminary safety
outcomes
P.W. Eiken1, T. de Baère2, F. Deschamps2, J. Palussière3, X. Buy3,
M.R. Callstrom1, D.A. Woodrum1, F. Abtin4, R.D. Suh4, B. Pua5, D.C. Madoff5,
D. Papadouris6, S. Bagla6, D.E. Dupuy7, T. Healey7, W. Moore8, S.B. Solomon5,
H. Yarmohammadi5, H. Krebs9; 1Rochester, MN/US, 2Villejuif/FR, 3Bordeaux/FR, 4Los Angeles, CA/US, 5New York, NY/US, 6Alexandria, VA/US, 7Providence, RI/US, 8Stony Brook, NY/US, 9Newnan, GA/US

SBRT – current status and evidence
L.M. Kenny (Brisbane, QLD/AU)
Thermal ablation – current status and evidence
T. de Baère (Villejuif/FR)
Round-table discussion
   
   
  08:30-10:00, Auditorium 2 (Barria Room 1)
  Clinical Focus Session
CF 802 Understanding tumour biology
   
  Moderators: P. Gibbs (Melbourne, VIC/AU), N. Goldberg (Jerusalem/IL)
   
802.1
 
802.2
 
802.3
 
802.4
 
802.5
 
Hypoxia and anoxia – friend or enemy?
B.J. Wood (Bethesda, MD/US)
IO procedures inducing tumour spread
C.T. Sofocleous (New York, NY/US)
Post-ablation inflammation and immune reactions – the bad
N. Goldberg (Jerusalem/IL)
Post-ablation inflammation and immune reactions – the good
M.H.M.G.M. den Brok (Nijmegen/NL)
Combined locoregional and systemic immunotherapy
L. Tselikas (Villejuif/FR)
   
   
  10:30-11:30, Main Auditorium (Sala A1)
HL 901 Honorary Lecture
   
  Moderators: J.I. Bilbao (Pamplona/ES), E. Brountzos (Athens/GR)
   
  Laudation: A. Gangi (Strasbourg/FR)
   
901.1
 
 
Metastatic colorectal cancer and percutaneous thermal ablation:
a happy marriage?
J. Palussière (Bordeaux/FR)
   
   
  10:30-12:00, HDT Room (Sala A3)
  Hands-on Device Training
TA-HDT 3 Tumour ablation – Microwave
   
  Please click here for further details.
   
   
  11:30-12:00, Main Auditorium (Sala A1)
  Paper Session
PS 902 The best IO papers of 2016
   
  Moderators: J.I. Bilbao (Pamplona/ES), E. Brountzos (Athens/GR)
   
902.1 Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response
C.E.N.M. Rosenbaum, A.F. van den Hoven, M.N.G.J.A. Braat, M. Koopman,
M.G.E.H. Lam, B.A. Zonnenberg, H.M. Verkooijen, M.A.A.J. van den Bosch;
Utrecht/NL
902.2 Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma
R. Hickey, S. Mouli, L. Kulik, K. Desai, B. Thornburg, D. Ganger, T. Baker,
M. Abecassis, J. Ralph Kallini, A. Gabr, V.L. Gates, A.B. Benson III,
R.J. Lewandowski, R. Salem; Chicago, IL/US
902.3 Pharmacokinetics, safety, and efficacy of chemoembolization with doxorubicin-loaded tightly calibrated small microspheres in patients with hepatocellular carcinoma
K. Malagari, T. Kiakidis, M. Pomoni, H. Moschouris, E. Emmanouil,
T. Spiridopoulos, V. Sotirchos, S. Tandeles, D. Koundouras, A. Kelekis,
D. Filippiadis, A. Charokopakis, E. Bouma, A. Chatziioannou, S. Dourakis,
J. Koskinas, T. Karampelas, K. Tamvakopoulos, N. Kelekis, D. Kelekis;
Athens/GR
   
   
  13:00-14:30
  Satellite Symposia
   
   
  15:00-16:30, Auditorium 2 (Barria Room 1)
  Multidisciplinary Tumour Board
MTB 1101 Lung tumours – beyond the guidelines
   
  Coordinator: J. Palussière (Bordeaux/FR)
   
  Panellists: J. Aristu (Pamplona/ES), A. Gillams (London/UK),
J. Jougon (Pessac/FR), U. Martens (Heilbronn/DE)
   
   
  15:00-16:30, Main Auditorium (Sala A1)
  Clinical Focus Session
CF 1102 IO in HCC: early and intermediate
   
  Moderators: R. Golfieri (Bologna/IT), B. Sangro (Pamplona/ES)
   
1102.1
 
1102.2
 
1102.3
 
1102.4
 
1102.5
 
From Barcelona to Hong Kong: the HCC classifications
B. Sangro (Pamplona/ES)
What to do when on the waiting list for transplantation
V. Mazzaferro (Milan/IT)
Local ablation in early stage: do we compete with surgery?
L. Crocetti (Pisa/IT)
Intermediate stage: is there room for radioembolisation?
R. Salem (Chicago, IL/US)
Intermediate stage: what are the indications for combined therapy?
T.F. Jakobs (Munich/DE)
   
   
  15:00-16:30, HDT Room (Sala A3)
  Hands-on Device Training
TA-HDT 4 Tumour ablation – Microwave
   
  Please click here for further details.
   
   
  17:00-18:30, Main Auditorium (Sala A1)
  Clinical Focus Session
CF 1201 IO in HCC: what's new?
   
  Moderators: V. Mazzaferro (Milan/IT), J. Urbano (Madrid/ES)
   
1201.1
 
1201.2
 
1201.3
 
1201.4
 
1201.5
 
1201.6
 
1201.7
 
Current status of classifying HCC and tailoring therapy: an update
J.-F.H. Geschwind (New Haven, CT/US)
New drugs in advanced HCC
B. Sangro (Pamplona/ES)
Bland embolisation vs. drug-eluting beads: the evidence
K. Malagari (Athens/GR)
RF vs. microwave in tumours up to 4 cm: the evidence
A. Denys (Lausanne/CH)
Cryoablation vs. RF
P.B. Shyn (Boston, MA/US)
SARAH trial – late breaking data
V. Vilgrain (Clichy/FR)
Idarubicin TACE
B. Guiu (Montpellier/FR)
   
   
  17:00-18:30, Auditorium 2 (Barria Room 1)
  Clinical Focus Session
CF 1202 Primary lung cancer
   
  Moderators: G. Bastarrika (Pamplona/ES), J. Palussière (Bordeaux/FR)
   
1202.1
 
1202.2
 
 
1202.3
 
 
1202.4
 
1202.5
 
1202.6
 
An update of systemic therapy of NSCLC
U. Martens (Heilbronn/DE)
Surgery, SBRT, local ablation: an appraisal of the pre- and post-treatment
lung function
E. Quoix (Strasbourg/FR)
Invited scientific paper: Microwave ablation for lung neoplasms: a retrospective analysis of long-term results
T.T. Healey, B.T. March, G. Baird, D.E. Dupuy; Providence, RI/US
SBRT
J. Aristu (Pamplona/ES)
Local ablation
X. Buy (Bordeaux/FR)
Imaging follow-up of SBRT and ablation
R.D. Suh (Los Angeles, CA/US)
   

TOP

 

Tuesday, April 25

   
  08:30-10:00, Auditorium 2 (Barria Room 1)
  Clinical Focus Session
CF 1501 Breast cancer patients – the IO add-on
   
  Moderators: E. Aranda (Córdoba/ES), F. Orsi (Milan/IT)
   
1501.1
 
1501.2
 
1501.3
 
1501.4
 
 
 
1501.5
 
1501.6
 
Demographics and need for treatment
A. Urrutikoetxea (San Sebastián/ES)
Local treatment in metastatic breast cancer: the oncologist's perspective
J.-E. Kurtz (Strasbourg/FR)
Ablation of breast tumours
J. Palussière (Bordeaux/FR)
Invited scientific paper: Percutaneous thermal ablation of breast cancer metastases in oligometastatic patients
M. Barral1, A. Auperin1, A. Hakimé1, V. Cartier1, V. Tacher1, Y. Otmezguine2,
L. Tselikas1, T. de Baère1, F. Deschamps1; 1Villejuif/FR, 2Boulogne-Billancourt/FR

IO in metastatic liver disease
F. Orsi (Milan/IT)
IO in metastatic bone disease
D.K. Filippiadis (Athens/GR)
   
   
  08:30-10:00, Main Auditorium (Sala A1)
  Video Learning Session
VL 1502 How I do it – lung, kidney, bone
   
  Moderators: X. Serrés (Barcelona/ES)
Commentator: D.J. Breen (Southampton/UK)
   
1502.1
 
1502.2
 
1502.3
 
1502.4
 
Lung cryoablation
F. Deschamps (Villejuif/FR)
Kidney microwave ablation
J.L. Hinshaw (Madison, WI/US)
Bone consolidation
J. Garnon (Strasbourg/FR)
Thyroid radiofrequency ablation
F. Stacul (Trieste/IT)
   
   
  10:30-12:00, Auditorium 2 (Barria Room 1)
  Clinical Focus Session
CF 1601 MSK tumours beyond the spine
   
  Moderators: M.R. Callstrom (Rochester, MN/US), A.D. Kelekis (Athens/GR)
   
1601.1
 
1601.2
 
1601.3
 
 
 
1601.4
 
1601.5
 
1601.6
 
Bone consolidation in cancer patients: biomechanical and surgical
P.J. Papagelopoulos (Athens/GR)
Indications and limits of SBRT
S. Myrehaug (Toronto, ON/CA)
Invited scientific paper: Percutaneous internal fixation to prevent impeding pathological hip fractures: a 1-year follow-up study
F. Deschamps1, T. Carteret2, L. Tselikas1, B. Lapuyade2, T. de Baère1,
F. Cornelis2; 1Villejuif/FR, 2Bordeaux/FR

Ablation and consolidation
R.-T. Hoffmann (Dresden/DE)
Management of benign bone tumours excluding osteoid osteoma
J. Jennings (St. Louis, MO/US)
Treatment options for soft tissue tumours
X. Buy (Bordeaux/FR)
   
   
  10:30-12:00, Main Auditorium (Sala A1)
  Clinical Focus Session
CF 1602 Complication management
   
  Moderators: P. Reimer (Karlsruhe/DE), O.M. van Delden (Amsterdam/NL)
   
1602.1
 
1602.2
 
1602.3
 
1602.4
 
1602.5
 
1602.6
 
Liver thermal ablation
L. Solbiati (Rozzano/IT)
TACE
Y. Arai (Tokyo/JP)
Radioembolisation
B. Peynircioglu (Ankara/TR)
Kidney cryoablation
D.J. Breen (Southampton/UK)
Lung ablation
R.D. Suh (Los Angeles, CA/US)
Bone ablation
J. Garnon (Strasbourg/FR)
   
   
  10:30-12:00, HDT Room (Sala A3)
  Hands-on Device Training
TA-HDT 5 Tumour ablation – Alternative techniques and image guidance
   
  Please click here for further details.
   
   
  13:00-14:30
  Satellite Symposia
   
   
  15:00-16:30, Auditorium 2 (Barria Room 1)
  Clinical Focus Session
CF 1801 Genomics in cancer
   
  Moderators: B. Costa-Silva (Lisbon/PT), R. Lencioni (Miami, FL/US)
   
1801.1
 
1801.2
 
1801.3
 
1801.4
 
1801.5
 
Genomics – a general concept?
R.B. Corcoran (Boston, MA/US)
Is genomics changing the percutaneous biopsy business?
G. Frija (Paris/FR)
Radiomics in MRI
D. Bonekamp (Heidelberg/DE)
Radiomics – new markers in PET-CT
N. Schäfer (Lausanne/CH)
Iomics – what could it mean?
R. Lencioni (Miami, FL/US)
   
   
  15:00-16:30, Main Auditorium (Sala A1)
  Video Learning Session
VL 1802 How I do it – liver
   
  Moderator: A. Denys (Lausanne/CH)
Commentator: P.E. Huppert (Darmstadt/DE)
   
1802.1
 
1802.2
 
1802.3
 
1802.4
 
1802.5
 
Complex liver thermal ablation
P. Chevallier (Nice/FR)
Liver DEB-TACE
R. Golfieri (Bologna/IT)
Liver balloon TACE
T. de Baère (Villejuif/FR)
Liver radioembolisation
P. Reimer (Karlsruhe/DE)
Portal vein and hepatic vein embolisation
R. Duran (Lausanne/CH)
   
   
  17:00-18:30, Main Auditorium (Sala A1)
  Clinical Focus Session
CF 1901 Spinal tumours
   
  Moderators: A. Gangi (Strasbourg/FR), J.W. Jennings (Saint Louis, MO/US)
   
1901.1
 
1901.2
 
1901.3
 
 
 
 
 
 
1901.4
 
1901.5
 
1901.6
 
Spinal surgery in cancer patients
J.-P. Steib (Strasbourg/FR)
Indications and limits of SBRT
L.M. Kenny (Brisbane, QLD/AU)
Invited scientific paper: The Metastatic Spine Disease Multidisciplinary Working Group algorithms
A.N. Wallace1, C.G. Robinson1, J. Meyer2, N.D. Tran3, A. Gangi4, M.R. Callstrom5, S.T. Chao6, B.A. Van Tine1, J.M. Morris5, B.M. Bruel7, J. Long1,
R.D. Timmerman2, J.M. Buchowski1, J.W. Jennings1; 1Saint Louis, MO/US,
2Dallas, TX/US, 3Tampa, FL/US, 4Strasbourg/FR, 5Rochester, MN/US,
6Cleveland, OH/US, 7Houston, TX/US

Ablation and augmentation
J. Jennings (St. Louis, MO/US)
Management of benign tumours
A.D. Kelekis (Athens/GR)
The role of embolisation
L. Hechelhammer (St. Gallen/CH)
   
   
  17:00-18:30, Auditorium 2 (Barria Room 1)
  Clinical Focus Session
CF 1902 Promoting IO evidence
   
  Moderators: L. Donoso (Barcelona/ES), P.L. Pereira (Heilbronn/DE)
   
1902.1
 
1902.2
 
1902.3
 
1902.4
 
1902.5
 
CIRT
J.I. Bilbao (Pamplona/ES)
CIREL
P.L. Pereira (Heilbronn/DE)
Overview ongoing studies
V. Vilgrain (Clichy/FR)
How to bring a product to market?
N.T. Lange (Bonn/DE)
The value of registries vs. randomised trials
G.J. Poston (Liverpool/UK)
   

TOP

 

Wednesday, April 26

   
  08:30-10:00, Main Auditorium (Sala A1)
  Clinical Focus Session
CF 2101 Kidney tumours
   
  Moderators: J.C. Durack (New York, NY/US), D.K. Filippiadis (Athens/GR)
   
2101.1
 
2101.2
 
2101.3
 
2101.4
 
2101.5
 
Demographics and need for treatment
J.E. Robles (Pamplona/ES)
Evidence-based nephron-sparing surgery
B.W. Lagerveld (Amsterdam/NL)
Evidence-based ablation vs. resection outcomes
D.J. Breen (Southampton/UK)
Palliative intervention in metastatic renal tumours
M.R. Callstrom (Rochester, MN/US)
The CIRSE SOP paper on RCC (cT1a)
M.E. Krokidis (Cambridge/UK)
   
   
  08:30-10:00, Auditorium 2 (Barria Room 1)
  Clinical Focus Session
CF 2102 Recipes for general patient management
   
  Moderators: P.E. Bize (Genolier/CH), F. Orsi (Milan/IT)
   
2102.1
 
2102.2
 
2102.3
 
2102.4
 
2102.5
 
2102.6
 
Assessing the patient's general condition
M. Fuchs (Munich/DE)
Analgosedation vs. ITN
R. Bale (Innsbruck/AT)
Peri-interventional pain management
A. Vari (Rome/IT)
Peri-interventional antibiotics
G. Maleux (Leuven/BE)
Anticoagulation and anti-aggregants: how to deal with them
J.A. Páramo (Pamplona/ES)
Postembolisation syndrome management
B. Gebauer (Berlin/DE)
   
   
  10:00-10:45
  Satellite Symposium
   
   
  11:15-12:45, Main Auditorium (Sala A1)
MM 2201 Morbidity & Mortality Conference
   
  Coordinators: M. Burrel (Barcelona/ES), P. Chevallier (Nice/FR)
   
2201.1
 
2201.2
 
2201.3
 
2201.4
 
 
 
2201.5
 
 
2201.6
 
 
Retrievable IVC filters: not so innocuous
E. Escalante (Barcelona/ES)
How should we treat large unilobar HCC?
M. Ronot (Clichy/FR)
Sizing the 'Big Thinking' in multimodality liver therapies
M. González Leyte (Madrid/ES)
Takotsubo cardiomyopathy after vertebroplasty of painful vertebral metastases of malignant adrenal pheochromocytoma
V. Catena (Bordeaux/FR)
Co-authors: X. Buy (Bordeaux/FR), J. Palussière (Bordeaux/FR)

Cardiac tamponade: a possible complication during radiofrequency (RF) ablation of colorectal lung metastasis
R.F. Grasso (Rome/IT)
Portal vein and arterial complications following pancreatic IRE: two cases and suggestions for prevention and treatment
M.R. Meijerink (Amsterdam/NL)
   

TOP